IntroductIon
Hepatocellular carcinoma (HCC) involving the inferior vena cava (IVC) or the right atrium (RA) is rare, occurring in less than 4% of all HCC patients. 1 The prognosis is poor with an expected survival time less than 3 months, if left untreated. 2 A standard treatment has not been established yet, as the incidence of the disease is rare and the treatment has a negative impact on the pulmonary and systemic circulation.
Although the Barcelona Clinic Liver Cancer staging criteria recommend sorafenib for treating HCC involving major vessels, 3 local treatments have been commonly performed in-stead, compensating for the poor tumor response with an expected longer survival. 4 External beam radiation therapy (EBRT) is a local treatment that is less affected by the tumor location unlike other local treatments. 5 In particular, radiofrequency ablation (RFA) or surgery is difficult for tumors involving major vessels or for those present in their vicinity, whereas EBRT is relatively more feasible. The estimated tolerance dose of radiation for major vessels, commonly extrapolated from studies on central lung tumors, 6 exceeds 100 Gy, which is enough for efficient control of the tumor. 7 Pioneering researchers tried using local therapies such as transarterial chemoembolization (TACE) and EBRT achieving successful tumor response rates for HCCs involving IVC and/or RA. 8, 9 Nonetheless, the life expectancy of patients with HCCs involving IVC and/or RA is still approximately 1 year, with most patients dying within 2 years even after rigorous local treatments. 10 We shall review and report here a case of HCC involving IVC and RA treated with active local treatments, including EBRT, in which the patient survived for up to 7 years in a disease-free state until the last follow-up.
cASE rEPort
A 62-year-old man experienced upper-right abdominal pain after a fall and was referred to us by a private clinic after a fracture of the 10th rib was suspected following an X-ray examination. We performed abdominal ultrasonography and incidentally found a liver mass. The patient reported no his- 
dIScuSSIon
Recently, Samsung Medical Center, one of the high-volume centers in Korea, published a study showing that HCC patients who were treated with a multidisciplinary approach had a higher survival rate than the control group. 11 As there are different staging systems for grading HCC, multiple treatment options are available for even for the same stage of disease. 12 Some researchers describe those considerations as a 'fierce battle'; 13 8, 16 In a recent pooled meta-analysis, the tumor response rate to EBRT of HCC involving IVC and/or RA exceeded 60%, and the local control rate was as high as 84%. 10 A theoretical concern has been raised, that treating HCC involving IVC and/or RA with potent local treatments such as EBRT could lead to pulmonary embolism or sudden death due to a dropped-out necrotized stalk. 17 However, only one case of pulmonary embolism was reported in a meta-analysis of 192 patients, and the rate of grade ≥3 complications was only 1.2%. 10 Hence, we consider EBRT for HCC involving IVC and/or RA a feasible local treatment strategy.
In a study by Hou et al. 16 , intrahepatic tumor numbers and their control status affected the survival rate of patients with HCC involving IVC. Koo et al. 17 reported that liver function and the invasion of the portal vein are significant factors affecting the survival. Two studies indicated IVC thrombosis response and combined treatment of TACE and EBRT as strong predictors of survival. 16, 17 Although a definitive cure might be difficult even for cases satisfying all the above prognosticators, our case suggests the possibility that active multimodality treatment for localized HCC involving IVC and/ or RA could result in long-term survival.
Although we did not need any systemic agents other than sorafenib for this case, regorafenib 18 and carbozantinib 19 have successfully shown survival benefit and can be used as second-line drugs if sorafenib fails. Many ongoing trials are evaluating the efficacy and feasibility of combined treatments
